Back to search results
NCT07652580

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

Recruiting
Not specifiedAges 4+Observational
Henry M. Jackson Foundation for the Advancement of Military Medicine
~300 participants
Updated 2026-09-03 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Aim 1: Characterize occupational exposures and their impact on health outcomes and immune health of ADSMs and other MHS beneficiaries with B-cell NHL.
Measured over 3 years
+2 more outcomes measured

Conditions

Non-Hodgkin Lymphoma
Lymphoma Non-Hodgkin
B-cell Lymphoma
Immune Dysregulation

Explore related trials

B-Cell Non-Hodgkin Lymphoma

NCT07652580

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Walter Reed National Military Medical Center

    Bethesda, Marylandstudy coordinator listed

    Recruiting

  • Naval Medical Center Portsmouth

    Portsmouth, Virginiano site contact published

    Active, not recruiting

  • Uniformed Services University of the Health Sciences

    Bethesda, Marylandno site contact published

    Active, not recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Christin Destefano · PRINCIPAL_INVESTIGATOR · Uniformed Services University of the Health Sciences

Who to contact

Christin B. Destefano, MD, Lt Col, MC, USAF
[email protected]
(301) 295-3190
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 4 years old and older with a clinical diagnosis of B-cell NHL.
Must be willing to undergo phlebotomy and/or skin punch biopsy.
Must be willing to undergo whole genome sequencing, which includes return of primary and secondary findings.

Exclusion

Has any condition that, in the opinion of the Principal Investigator, contraindicates participation in this study. Examples of situation that may contraindicate participation include but are not limited to a) some cases of cerebral vascular accidents where an individual no longer has the capacity to make their own medical decisions and a conservator or responsible family member is not available and b) an individual has active suicidal ideation and is a danger to themselves at the time of enrollment.
Does not have access to health care and primary care clinician.
Actively undergoing induction treatment for NHL.

What this trial measures

  • Aim 1: Characterize occupational exposures and their impact on health outcomes and immune health of ADSMs and other MHS beneficiaries with B-cell NHL.3 years

    1. Characterize and determine the prevalence of various toxin and occupational exposures in ADSMs and other MHS beneficiaries with B-cell NHL (Cohorts 1-3). 2. Characterize the B-cell NHL subtypes and health outcomes of NHL in ADSMs and other MHS beneficiaries (Cohorts 1-3). 3. Characterize immune dysregulation in ADSMs and other MHS beneficiaries with B-cell NHL. Immune dysregulation could be characterized by humoral vs cellular defects as well as innate vs adaptive defects among others (Cohorts 2-3).

  • Aim 2: Identify and interpret germline variants in ADSMs and other MHS beneficiaries with B-cell NHL.3 years

    1\. Determine the relative frequency of germline pathogenic/likely pathogenic variants in MHS beneficiaries with B-cell NHL (Cohorts 1-3).

  • Aim 3: Create a comprehensive database and biorepository of ADSMs and other MHS beneficiaries with B-cell NHL.3 years

    1. Create a database compiling clinical information, toxin exposure, military history (if applicable), and health outcomes (Cohorts 1-3). 2. Create a biorespository of peripheral blood (Cohorts 1-3).